Q1 2022 Results
Company overview
Financial performance
CRM
Immunology
Financial review
Neuroscience
2022 priorities
Innovation: Pipeline overview
Ophthalmology
Appendix
Innovation: Clinical trials
Respiratory & Allergy
Oncology: Solid Tumors
sabatolimab - TIM3 antagonist
Study
Indication
Phase
Patients
Primary Outcome
Measures
NCT04266301 STIMULUS-MDS2 (CMBG453B12301)
Myelodysplastic syndrome
Phase 3
500
Overall survival
Arms Intervention
Sabatolimab 800 mg + azacitidine 75 mg/m2
Sabatolimab 800 mg + azacitidine 75 mg/m2 + placebo
Patients with intermediate, high or very high risk Myelodysplastic Syndrome (MDS)
as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Target Patients
Read-out Milestone(s)
2023
Publication
TBD
References
Abbreviations
Hematology
Biosimilars
Global Health
113 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation